Sudo Biosciences
Sudo Biosciences: A biopharmaceutical leader in designing novel, transformative medicines.
Founded
2020Sudo Biosciences: A biopharmaceutical leader in designing novel, transformative medicines.
Sudo Biosciences, a biopharmaceutical company, was founded with the mission to design and develop novel, best-in-class medicines aimed at transforming patients' lives. The company focuses on targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, a key mediator in cytokine signaling pathways linked to various immune-mediated inflammatory conditions. Sudo Biosciences' pipeline includes next-generation TYK2 inhibitors, positioning them as potential first- and best-in-class therapeutics in this area.
Notable figures affiliated with Sudo Biosciences include leading scientists and industry experts who drive the company's innovative research and development efforts. The company has garnered attention from prominent investors in the biopharmaceutical sector, reflecting confidence in its groundbreaking approach. Key achievements include advancing their lead programs through critical development stages, which underscores their potential impact on treating immune-mediated inflammatory diseases. Sudo Biosciences continues to make significant strides in biopharmaceutical innovation, aiming to improve patient outcomes globally.
Companies similar to Sudo Biosciences include Sudhin Biopharma, Pyramid Biosciences, Judo Bio and EydisBio.
Sudo Biosciences was founded in 2020.
Sudo Biosciences' headquarters is located in Menlo Park, CA, US.
Sudo Biosciences' most recent funding round was for $116M (USD) in December 2023.
As of Dec 20, 2023, Sudo Biosciences has disclosed funding of $153M (USD). Undisclosed round amounts are excluded.
Sudo Biosciences has 11 employees as of Feb 5, 2024.
eydisbio.com
